Changeflow GovPing Healthcare & Life Sciences Phage-Derived Particles Deliver DNA Into C. Acn...
Routine Notice Added Final

Phage-Derived Particles Deliver DNA Into C. Acnes, Eligo Bioscience

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

USPTO published patent application US20260109991A1 by Eligo Bioscience on April 23, 2026, covering phage-derived particles for delivering DNA payloads into Cutibacterium acnes bacteria. The application, filed October 24, 2025, discloses engineered vectors with C. acnes phage packaging signals and genes of interest, along with producer cells, phage-derived particles, and methods for transducing C. acnes with transgenes. Inventors include Aymeric LEVEAU, Ines CANADAS BLASCO, Aurelie MATHIEU, and Antoine DECRULLE.

“The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 199 changes logged to date.

What changed

USPTO published Eligo Bioscience's patent application covering engineered C. acnes phage-derived particles capable of robustly transducing C. acnes receiver cells with genes of interest. The application discloses vectors with C. acnes phage packaging signals, producer cells carrying these vectors, and methods for transgene expression in modified C. acnes.

Affected parties include developers of microbiome therapeutics, dermatological treatments, and synthetic biology applications involving Cutibacterium acnes. Biotech and pharmaceutical companies working on phage therapy platforms or acne treatments should monitor this application's prosecution for potential freedom-to-operate implications.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PHAGE-DERIVED PARTICLES FOR IN SITU DELIVERY OF DNA PAYLOAD INTO C. ACNES POPULATION

Application US20260109991A1 Kind: A1 Apr 23, 2026

Assignee

Eligo Bioscience

Inventors

Aymeric LEVEAU, Ines CANADAS BLASCO, Aurelie MATHIEU, Antoine DECRULLE

Abstract

The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.

CPC Classifications

C12N 15/76 A61K 39/02 A61K 39/05 A61P 17/10 C12N 9/22 C12N 15/11 A61K 2039/53 C12N 9/64 C12N 2310/20 C12N 2795/10343 C12N 2800/101 C12N 2800/80

Filing Date

2025-10-24

Application No.

19368024

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Drug manufacturers Healthcare providers
Industry sector
3254.1 Biotechnology
Activity scope
Patent filing Biotech research and development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!